DHX9 and Ewing sarcoma: In this scenario, the development of antisense oligonucleotides (ASOs) recruiting the spliceosomal complex to the alternative exon 6A in RHA could be instrumental to drive RHA downregulation in live cells and might provide a valuable additional therapy for the treatment of Ewing sarcoma.